Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes

DCCT/EDIC Research Group, David M Nathan, Ionut Bebu, Dean Hainsworth, Ronald Klein, William Tamborlane, Gayle Lorenzi, Rose Gubitosi-Klug, John M Lachin

Abstract

Background: In patients who have had type 1 diabetes for 5 years, current recommendations regarding screening for diabetic retinopathy include annual dilated retinal examinations to detect proliferative retinopathy or clinically significant macular edema, both of which require timely intervention to preserve vision. During 30 years of the Diabetes Control and Complications Trial (DCCT) and its longitudinal follow-up Epidemiology of Diabetes Interventions and Complications (EDIC) study, retinal photography was performed at intervals of 6 months to 4 years.

Methods: We used retinal photographs from the DCCT/EDIC study to develop a rational screening frequency for retinopathy. Markov modeling was used to determine the likelihood of progression to proliferative diabetic retinopathy or clinically significant macular edema in patients with various initial retinopathy levels (no retinopathy or mild, moderate, or severe nonproliferative diabetic retinopathy). The models included recognized risk factors for progression of retinopathy.

Results: Overall, the probability of progression to proliferative diabetic retinopathy or clinically significant macular edema was limited to approximately 5% between retinal screening examinations at 4 years among patients who had no retinopathy, 3 years among those with mild retinopathy, 6 months among those with moderate retinopathy, and 3 months among those with severe nonproliferative diabetic retinopathy. The risk of progression was also closely related to mean glycated hemoglobin levels. The risk of progression from no retinopathy to proliferative diabetic retinopathy or clinically significant macular edema was 1.0% over 5 years among patients with a glycated hemoglobin level of 6%, as compared with 4.3% over 3 years among patients with a glycated hemoglobin level of 10%. Over a 20-year period, the frequency of eye examinations was 58% lower with our practical, evidence-based schedule than with routine annual examinations, which resulted in substantial cost savings.

Conclusions: Our model for establishing an individualized schedule for retinopathy screening on the basis of the patient's current state of retinopathy and glycated hemoglobin level reduced the frequency of eye examinations without delaying the diagnosis of clinically significant disease. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; DCCT/EDIC ClinicalTrials.gov numbers, NCT00360893 and NCT00360815 .).

Figures

Figure 1
Figure 1
Cumulative Incidence of State 5 Retinopathy (Proliferative Diabetic Retinopathy or Clinically Significant Macular Edema).

References

    1. National diabetes fact sheet, 2011: national estimates and general information on diabetes and prediabetes in the United States. Atlanta: Centers for Disease Control and Prevention; 2011.
    1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.
    1. Lachin JM, White NH, Hainsworth DP, Sun W, Cleary PA, Nathan DM. Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes. 2015;64:631–42.
    1. The DCCT/EDIC Research Group. Intensive diabetes therapy and ocular surgery in type 1 diabetes. N Engl J Med. 2015;372:1722–33.
    1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352:837–53.
    1. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366:1227–39.
    1. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of Diabetic Retinopathy Study findings. Ophthalmology. 1978;85:82–106.
    1. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796–806.
    1. Wang JK, Huang TL, Su PY, Chang PY. An updated review of long-term outcomes from randomized controlled trials in approved pharmaceuticals for diabetic macular edema. Eye Sci. 2015;30:176–83.
    1. American College of Physicians, American Diabetes Association, American Academy of Ophthalmology. Screening guidelines for diabetic retinopathy. Ann Intern Med. 1992;116:683–5.
    1. American Diabetes Association. Standards of medical care. Diabetes Care. 2017;40(Suppl 1):S88–S98.
    1. American Academy of Ophthalmology. Screening for diabetic retinopathy. 2014 Rev. ed. ( )
    1. Nathan DM, Zinman B, Cleary PA, et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh Epidemiology of Diabetes Complications experience (1983–2005) Arch Intern Med. 2009;169:1307–16.
    1. The DCCT/EDIC Research Group. Epidemiology of Diabetes Interventions and Complications (EDIC): design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care. 1999;22:99–111.
    1. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology. 1991;98(Suppl):766–85.
    1. Nathan DM, Bayless M, Cleary P, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study at 30 years: advances and contributions. Diabetes. 2013;62:3976–86.
    1. Cox DR. The theory of stochastic processes. London: Methuen; 1965.
    1. Jackson CH. Multi-state models for panel data: the msm package for R. J Stat Softw. 2011;38(8):1–29.
    1. Bebu I, Lachin JM. Optimal screening schedules for disease progression. Biostatistics. 2017 doi: 10.1093/biostatistics/kxx009.
    1. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN DCCT/EDIC Research Group. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial — revisited. Diabetes. 2008;57:995–1001.
    1. Aspelund T, Thornórisdóttir O, Olafsdottir E, et al. Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy. Diabetologia. 2011;54:2525–32.
    1. van der Heijden AA, Walraven I, van’t Riet E, et al. Validation of a model to estimate personalized screening frequency to monitor diabetic retinopathy. Diabetologia. 2014;57:1332–8.
    1. Liu Y, Wang M, Morris AD, et al. Glycemic exposure and blood pressure influencing progression and remission of diabetic retinopathy: a longitudinal cohort study in GoDARTS. Diabetes Care. 2013;36:3979–84.
    1. Marshall G, Jones RH. Multi-state models and diabetic retinopathy. Stat Med. 1995;14:1975–83.
    1. Dasbach EJ, Fryback DG, Newcomb PA, Klein R, Klein BEK. Cost-effectiveness of strategies for detecting diabetic retinopathy. Med Care. 1991;29:20–39.
    1. Looker HC, Nyangoma SO, Cromie DT, et al. Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme. Diabetologia. 2013;56:1716–25.
    1. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007;298:902–16.
    1. Mansberger SL, Sheppler C, Barker G, et al. Long-term comparative effectiveness of telemedicine in providing diabetic retinopathy screening examinations: a randomized clinical trial. JAMA Ophthalmol. 2015;133:518–25.
    1. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond) 2015;2:17–42.
    1. Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. Diabetes Care. 2000;23:1084–91.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться